Middle East Plasmid DNA Manufacturing Market To Reach $186.5 Million By 2033

Middle East Plasmid DNA Manufacturing Market Growth & Trends

The Middle East plasmid DNA manufacturing market size is projected to reach USD 186.5 million by 2033, growing at a CAGR of 17.43% from 2025 to 2033, according to a new report by Grand View Research, Inc. The market is expanding steadily, driven by the rising demand for advanced genetic therapies, increasing prevalence of chronic and rare diseases, and growing adoption of plasmid-based vectors in vaccines, cell & gene therapies, and cancer treatments. Strong government support, significant investment in biotechnology infrastructure, and the establishment of GMP-certified facilities are further enhancing regional production capabilities. Strategic collaborations between local players and global biotech companies are accelerating technology transfer and innovation, positioning the region as an emerging hub for plasmid DNA manufacturing to meet both domestic and international demand over the forecast period.

The emergence of DNA vaccine programs is further boosting the Middle East plasmid DNA manufacturing market, with post-COVID momentum and active R&D for diseases like MERS driving demand. Government funding, clinical trials, and global biotech collaborations are accelerating production capabilities and long-term growth.

However, limited regional manufacturing infrastructure continues to challenge the Middle East plasmid DNA manufacturing market, as the region relies heavily on imports for high-purity plasmid DNA. The absence of large-scale GMP-certified facilities restricts domestic production, increasing costs and supply chain dependency.

 Request a free sample copy or view report summary: Middle East Plasmid DNA Manufacturing Market Report

Middle East Plasmid DNA Manufacturing Market Report Segmentation

• By grade, GMP dominated the market in 2024 and is anticipated to grow at the fastest CAGR over the forecast period. This dominance is driven by the stringent regulatory requirements, rising demand for high-quality plasmid DNA in clinical trials, and the expansion of GMP-certified manufacturing facilities across the region.

• By development phase, clinical therapeutics dominated the market in 2024 with a share of 55.53%. This dominance is driven by increasing adoption of plasmid DNA in advanced therapies, expanding clinical trial pipelines, and rising investments in gene-based drug development across the region. On the other hand, pre-clinical therapeutics is anticipated to grow at the fastest CAGR over the forecast period.

• By application, the cell & gene therapy segment led the market in 2024, owing to the growing use of plasmid-based vectors in CAR-T cell therapy, gene editing, and regenerative medicine, supported by government funding and GMP-certified manufacturing expansion. Moreover, the DNA vaccine segment is forecasted to grow at the fastest rate over the period.

• By disease, cancer accounted for the largest market share of 38.43% in 2024 and is anticipated to grow at the fastest CAGR over the forecast period. This is driven by rising cancer incidence, expanding oncology research, and increased adoption of plasmid-based cancer therapies.

Middle East Plasmid DNA Manufacturing Market Segmentation

Grand View Research has segmented the Middle East plasmid DNA manufacturing market on the basis of grade, development phase, application, disease, and country:

Middle East Plasmid DNA Manufacturing Grade Outlook (Revenue, USD Million, 2021 - 2033)

• R&D Grade

  • Viral Vector Development

    • AAV

    • Lentivirus

    • Adenovirus

    • Retrovirus

    • Others

  • mRNA Development

  • Antibody Development

  • DNA Vaccine Development

  • Others

• GMP Grade

Middle East Plasmid DNA Manufacturing Development Phase Outlook (Revenue, USD Million, 2021 - 2033)

• Pre-Clinical Therapeutics

• Clinical Therapeutics

• Marketed Therapeutics

Middle East Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2021 - 2033)

• DNA Vaccines

• Cell & Gene Therapy

• Immunotherapy

• Others

Middle East Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2021 - 2033)

• Infectious Disease

• Cancer

• Genetic Disorder

• Others

Middle East Plasmid DNA Manufacturing Country Outlook (Revenue, USD Million, 2021 - 2033)

• Saudi Arabia

• UAE

• Kuwait

• Qatar

• Oman

• Rest of Middle East

List of Key Players in Middle East Plasmid DNA Manufacturing Market

• Charles River Laboratories

• Danaher (Aldevron)

• Lonza Group

• VGXI, Inc.

• Kaneka Corp.

• Eurofins Genomics

• Luminous BioSciences, LLC

• Cell & Gene Therapy Catapult

• Nature Technology

• Akron Biotech